3-benzyl-6-carboxy-3,4-dihydro-benzothiazine-2,4-dione | 638205-07-9

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 3-benzyl-6-carboxy-3,4-dihydro-benzothiazine-2,4-dione
• 英文别名: 3-Benzyl-2,4-dioxo-1,3-benzothiazine-6-carboxylic acid
• CAS: 638205-07-9
• 化学式: C₁₆H₁₁NO₄S
• 分子量: 313.334
• InChiKey: KSUZTUOKNSMIHX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  100
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-benzyl-6-cyano-3, 4-dihydro-benzothiazine-2,4-dione 在 硫酸 、 水 作用下， 反应 3.0h， 以31%的产率得到3-benzyl-6-carboxy-3,4-dihydro-benzothiazine-2,4-dione
  参考文献：
  名称：

  [EN] THIAZINE AND OXAZINE DERIVATIVES AS MMP-13 INHIBITORS FOR TREATING ARTHRITIS
  [FR] DERIVES DE THIAZINE ET D'OXAZINE UTILISES EN TANT QU'INHIBITEURS MMP-13 POUR TRAITER L'ARTHRITE

  摘要：

  从式(I)中选择的一种化合物：其中：• X1、X2和X3代表氮或-CR3，其中R3代表氢、烷基、氨基、烷基氨基、二烷基氨基、羟基、烷氧基或卤素，• Gl代表氧或S(O)p，其中p为0至2，• G2代表碳-碳三键、C=O、C=S、S(O)q，其中q为0至2，或式(i/a)的基团：其中YI和Y2如描述中所定义，• n为0至6，Zl代表-CR4R5，其中R4和R5如描述中所定义，• A代表5-或6-成员单环或双环芳基、杂环芳基、环烷基或杂环烷基，• RI代表氢、烷基、烯基、炔基（这些基团可以按描述中定义进行选择性取代）或式(i/b)的基团：其中s、Z2、B、t和G3如描述中所定义，以及可选地，其光学异构体、N-氧化物，以及与药学上可接受的酸或碱形成的加合物，以及含有这些化合物的药物制剂可作为特异性抑制剂用于治疗关节炎和癌症等疾病。

  公开号：

  WO2004000322A1

文献信息

• Thiazine and oxazine derivatives as MMP-13 inhibitors
  申请人：——

  公开号：US20040006077A1

  公开（公告）日：2004-01-08

  The specification discloses compounds selected from those of formula (I): 1 or a racemic form, isomer, N-oxide, or pharmaceutically acceptable salt thereof, wherein R 2 , m, A, Z 1 , n, G 2 , X 1 , X 2 , X 3 , G 1 , and R 1 are as defined in the specification, wherein the compound of formula (I) is not 6-(2,4-dioxo-3,4-dihydro-2H-1,3-benzothiazine)-benzoate, 6-phenylthio-2,4-dioxo-3,4-dihydro-2H-1,3-benzothiazine, 6-benzylsulphonyl-2,4-dioxo-3,4-dihydro-2H-1,3-benzothiazine, 6-benzophenone-2,4-dioxo-3,4-dihydro-2H-1,3-benzothiazine or 6-(2,4-dihydroxy)-benzophenone-2,4-dioxo-3,4-dihydro-2H-1,3-benzothiazine. The specification also discloses processes for preparing the compounds, pharmaceutical compositions comprising said compounds of formula (I) or a racemic form, isomer, N-oxide, or pharmaceutically acceptable salt thereof, and methods of treating diseases or disorders mediated by a MMP-13 enzyme or responsive to treatment with an inhibitor of a MMP-13 enzyme, comprising administering said compounds of formula (I) or a racemic form, isomer, N-oxide, or pharmaceutically acceptable salt thereof.

  该规范披露了从以下公式(I)中选择的化合物：1或其消旋形式、异构体、N-氧化物或其药用可接受的盐，其中R2、m、A、Z1、n、G2、X1、X2、X3、G1和R1如规范中所定义，其中公式(I)的化合物不是6-(2,4-二氧代-3,4-二氢-2H-1,3-苯并噻嗪)-苯甲酸酯、6-苯硫基-2,4-二氧代-3,4-二氢-2H-1,3-苯并噻嗪、6-苄基磺酰基-2,4-二氧代-3,4-二氢-2H-1,3-苯并噻嗪、6-苯甲酮基-2,4-二氧代-3,4-二氢-2H-1,3-苯并噻嗪或6-(2,4-二羟基)-苯甲酮基-2,4-二氧代-3,4-二氢-2H-1,3-苯并噻嗪。该规范还披露了制备这些化合物的方法、包含上述公式(I)的化合物或其消旋形式、异构体、N-氧化物或其药用可接受的盐的药物组合物，以及用于治疗由MMP-13酶介导或对MMP-13酶抑制剂治疗反应的疾病或紊乱的方法，包括给予上述公式(I)的化合物或其消旋形式、异构体、N-氧化物或其药用可接受的盐。
• THIAZINE AND OXAZINE DERIVATIVES AS MMP-13 INHIBITORS FOR TREATING ARTHRITIS
  申请人：WARNER-LAMBERT COMPANY LLC

  公开号：EP1539176A1

  公开（公告）日：2005-06-15
• [EN] THIAZINE AND OXAZINE DERIVATIVES AS MMP-13 INHIBITORS FOR TREATING ARTHRITIS<br/>[FR] DERIVES DE THIAZINE ET D'OXAZINE EN TANT QU'INHIBITEURS DE MMP-13 POUR TRAITER L'ARTHRITE
  申请人：WARNER LAMBERT CO

  公开号：WO2004000321A1

  公开（公告）日：2003-12-31

  A compound selected from those of formula (I) wherein: X1, X2 and X3 represent nitrogen or -CR3 in which R3 represents hydrogen, alkyl, amino, alkylamino, dialkylamino, hydroxy, alkoxy, or halogen, G1 represents oxygen or S(O)p in which p is from 0 to 2, G2 represents carbon-carbon triple bond, C=O, C=S, S(O)q in which q is from 0 to 2, or a group of formula (i/a) in which Y1 and Y2 are as defined in the description, n is from 0 to 6, Z1 represents CR4R5. wherein R4 and R5 are as defined in the description, A represents 5- or 6-membered monocycle or bicycle aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, R1 represents hydrogen, alkyl, alkenyl, alkynyl, (these groups may be optionally substituted as defined in the description) or the group of formula (i/b) in which s, Z2, B, t and G3 are as defined in the description, and optionally, its optical isomers, N-oxide, and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same are useful as specific inhibitors of type-13 matrix metalloprotease, for the treatment of i.a arthritis and cancer.